[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642372":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":18,"centralContacts":40,"locations":49,"responsibleParty":214,"collaborators":18,"id":216,"slug":217,"hasResults":218,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":218,"sex":224,"minAge":225,"maxAge":18,"enrollmentInfo":226,"targetDuration":18,"studyType":229,"phases":230,"briefSummary":232,"conditions":233,"keywords":18,"overallStatus":52,"whyStopped":18,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":244},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy or Preferred Combination in 2L+ CRC","EXPERIMENTAL","Participants randomized to a treatment in 2:1 ratio",[13,14,15],"Drug: VS-7375","Drug: cetuximab","Drug: panitumumab",{"label":17,"type":10,"description":18,"interventionNames":19},"VS-7375 with chosen regimen in 2L+ CRC",null,[13,14,15],{"label":21,"type":10,"description":18,"interventionNames":22},"VS-7375 + cetuximab and mFOLFOX in 1L CRC",[23],"Drug: Cetuximab + mFOLFOX6",[25,30,34,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":18},"DRUG","VS-7375","Taken by mouth",[9,17],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":18},"cetuximab","Intravenous infusion",[9,17],{"type":26,"name":35,"description":32,"armGroupLabels":36,"otherNames":18},"panitumumab",[9,17],{"type":26,"name":38,"description":32,"armGroupLabels":39,"otherNames":18},"Cetuximab + mFOLFOX6",[21],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":18,"email":45},"Verastem Call Center","CONTACT","7812924204","VS-7375-203TrialSupport@verastem.com",{"name":47,"role":43,"phone":18,"phoneExt":18,"email":48},"Luke Chung, MD","VS-7375-203Medical@verastem.com",[50,72,85,102,117,132,147,162,179,197],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"START Los Angeles","RECRUITING","Los Angeles","California","90025","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-118.24368,34.05223,{"lat":62,"lon":61},[65,69],{"name":66,"role":43,"phone":67,"phoneExt":18,"email":68},"START Hope Team","424-465-1820","hopeteam@startresearch.com",{"name":70,"role":71,"phone":18,"phoneExt":18,"email":18},"Navid Hafez, M.D., MPH","PRINCIPAL_INVESTIGATOR",{"facility":73,"status":52,"city":53,"state":54,"zip":74,"country":56,"countryCode":57,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"Valkyrie Clinical Trials (contact for more locations)","90067",{"type":59,"coordinates":76},[61,62],{"lat":62,"lon":61},[79,83],{"name":80,"role":43,"phone":81,"phoneExt":18,"email":82},"Trenis Palmer, PhD","912-398-3205","trenis.palmer@vctcare.com",{"name":84,"role":71,"phone":18,"phoneExt":18,"email":18},"David Berz, MD, PhD, MPH",{"facility":86,"status":52,"city":87,"state":88,"zip":89,"country":56,"countryCode":57,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Moffitt Cancer Center","Tampa","Florida","33612",{"type":59,"coordinates":91},[92,93],-82.45843,27.94752,{"lat":93,"lon":92},[96,100],{"name":97,"role":43,"phone":98,"phoneExt":18,"email":99},"Cheyenne Schneider","813-745-3691","Cheyenne.Schneider@moffitt.org",{"name":101,"role":71,"phone":18,"phoneExt":18,"email":18},"Tiago Biachi de Castria, MD, PhD",{"facility":103,"status":52,"city":104,"state":105,"zip":106,"country":56,"countryCode":57,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"START Midwest","Grand Rapids","Michigan","49546",{"type":59,"coordinates":108},[109,110],-85.66809,42.96336,{"lat":110,"lon":109},[113,115],{"name":66,"role":43,"phone":114,"phoneExt":18,"email":68},"616-954-5554",{"name":116,"role":71,"phone":18,"phoneExt":18,"email":18},"Sreenivasa R Chandana, M.D., Ph.D.",{"facility":118,"status":52,"city":119,"state":120,"zip":121,"country":56,"countryCode":57,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"START New Jersey","East Brunswick","New Jersey","08816",{"type":59,"coordinates":123},[124,125],-74.41598,40.42788,{"lat":125,"lon":124},[128,130],{"name":66,"role":43,"phone":129,"phoneExt":18,"email":68},"732-426-4750",{"name":131,"role":71,"phone":18,"phoneExt":18,"email":18},"Bruno S Fang, M.D.",{"facility":133,"status":52,"city":134,"state":135,"zip":136,"country":56,"countryCode":57,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"START Dallas Fort Worth","Fort Worth","Texas","76104",{"type":59,"coordinates":138},[139,140],-97.32085,32.72541,{"lat":140,"lon":139},[143,145],{"name":66,"role":43,"phone":144,"phoneExt":18,"email":68},"682-350-3010",{"name":146,"role":71,"phone":18,"phoneExt":18,"email":18},"Salwan Al Mutar, M.D., M.Sc.",{"facility":148,"status":52,"city":149,"state":150,"zip":151,"country":56,"countryCode":57,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"START Mountain Region","West Valley City","Utah","84119",{"type":59,"coordinates":153},[154,155],-112.00105,40.69161,{"lat":155,"lon":154},[158,160],{"name":66,"role":43,"phone":159,"phoneExt":18,"email":68},"801-907-4750",{"name":161,"role":71,"phone":18,"phoneExt":18,"email":18},"José M Pacheco, M.D.",{"facility":163,"status":52,"city":164,"state":165,"zip":166,"country":56,"countryCode":57,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"UVA Comprehensive Cancer Center","Charlottesville","Virginia","22908",{"type":59,"coordinates":168},[169,170],-78.47668,38.02931,{"lat":170,"lon":169},[173,177],{"name":174,"role":43,"phone":175,"phoneExt":18,"email":176},"Clinical Trials Navigator","434-982-0539","UVACANCERTRIALS@uvahealth.org",{"name":178,"role":71,"phone":18,"phoneExt":18,"email":18},"Matthew Reilley, MD",{"facility":180,"status":52,"city":181,"state":182,"zip":183,"country":184,"countryCode":185,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Icon Cancer Centre South Brisbane","South Brisbane","Queensland","4101","Australia","AU",{"type":59,"coordinates":187},[188,189],153.02049,-27.48034,{"lat":189,"lon":188},[192,195],{"name":180,"role":43,"phone":193,"phoneExt":18,"email":194},"07 3737 4700","admin.southbrisbane@icon.team",{"name":196,"role":71,"phone":18,"phoneExt":18,"email":18},"Jermaine Coward, MBBS, MRCP (UK), FRACP, PhD",{"facility":198,"status":52,"city":199,"state":200,"zip":201,"country":184,"countryCode":185,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Icon Cancer Centre Adelaide","Kurralta Park","South Australia","5037",{"type":59,"coordinates":203},[204,205],138.56702,-34.95142,{"lat":205,"lon":204},[208,212],{"name":209,"role":43,"phone":210,"phoneExt":18,"email":211},"Icon Cancer Centre Adelaide\u002FKurralta Park","08 8474 0220","admin.adelaide@icon.team",{"name":213,"role":71,"phone":18,"phoneExt":18,"email":18},"Carolyn Bampton, MBBS, FRACP",{"type":215,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100642372","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-colorectal-cancer-100642372",false,"NCT07659795","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)","TARGET-D 203","Inclusion Criteria:\n\n* Histopathology confirmed metastatic CRC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\n  2L+ patients:\n* Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma\n* Have documented disease progression during or following their most recent prior line of therapy\n* Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.\n\n  1L patients:\n* Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* Receipt of prior direct RAS inhibitor\n* Receipt of more than 1 investigational therapy\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":227,"type":228},150,"ESTIMATED","INTERVENTIONAL",[231],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer",[234],"Colorectal Cancer","2026-08-07",{"date":237,"type":238},"2026-08-11","ACTUAL",{"date":240,"type":238},"2026-07-28",{"date":242,"type":228},"2028-12",{"name":5,"class":6},10]